The China Resources and Legend Holdings-backed vaccine technology developer floated in Hong Kong in a $97.7m offering following nearly $460m in funding.

Rec-Biotechnology (RecBio), the China-based vaccine developer backed by conglomerates China Resources and Legend Holdings, has raised HK$765m ($97.7m) in an initial public offering (IPO) on the Hong Kong Stock Exchange. The company issued nearly 30.9 million shares priced at HK$24.80 each. Subsidiaries of pharmaceutical firm Yangtze River Pharmaceutical Group, investment manager Harvest Global Investments and…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.